Expanded Eligibility for Third Doses of the COVID-19 Vaccine
Ontario has expanded third dose availability to additional highest risk groups as an extra layer of protection against the Delta variant. The following additional groups are now eligible for a third dose of COVID-19 vaccine at least eight weeks following their second dose:
- Those undergoing active treatment for solid tumors;
- Those who are in receipt of chimeric antigen receptor (CAR)-T-cell;
- Those with moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome);
- Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome; and
- Those undergoing active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive.
How to Refer Patients for 3rd Dose:
A COVID-19 Vaccine 3rd Dose Patient Referral Form can be completed ONLY when vaccination administration is unable to be completed intra-organizationally by a Physician or Specialty Program responsible for eligible patient care. To refer an eligible candidate for a 3rd dose of the COVID-19 vaccine, this form must be completed in full, signed, and shared with the patient who may present the form at an HPEPH clinic or participating pharmacy.
.png?1580149442840)
.png?1578593886679)